Emerging drugs for varicella-zoster virus infections

Expert Opinion on Emerging Drugs

Volumn 16, Issue 3, 2011, Pages 507-535

  Andrei, Graciela ^a   Snoeck, Robert ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

acyclic nucleoside phosphonates; ASP2151; FV 100; nucleoside analogs; post herpetic neuralgia; valomaciclovir; varicella zoster virus (VZV)

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; AMENAMEVIR; AZACITIDINE; CF 1368; CF 1742; CF 1743; CHICKENPOX VACCINE; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; DNA POLYMERASE; DNA PRIMASE; FAMCICLOVIR; FLAVOPIRIDOL; FV 100; HELICASE; NETIVUDINE; NUCLEOSIDE ANALOG; OLOMOUCINE; OMACICLOVIR; PENCICLOVIR; ROSCOVITINE; THYMIDINE; UNCLASSIFIED DRUG; VALACICLOVIR; VALOMACICLOVIR; VARICELLA ZOSTER VACCINE; ZERPEX; ZOSTEX;

AGING; CELLULAR IMMUNITY; CHICKENPOX; GOLD STANDARD; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; NONHUMAN; POSTHERPETIC NEURALGIA; REVIEW; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION;

ANIMALS; ANTIVIRAL AGENTS; CHICKENPOX; CHICKENPOX VACCINE; CLINICAL TRIALS AS TOPIC; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES, ATTENUATED;

EID: 80051959476     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2011.591786     Document Type: Review

References (179)

1. Breuer J, Whitley R. Varicella zoster virus: Natural history and current therapies of varicella and herpes zoster. Herpes 2007;14(Suppl 2):25-9
2. Gershon AA, Gershon MD, Breuer J, et al. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010;48(Suppl 1):S2-7 Excellent review of the pathogenesis and epidemiology of herpes zoster.
3. Beby-Defaux A, Brabant S, Chatellier D, et al. Disseminated varicella with multiorgan failure in an immunocompetent adult. J Med Virol 2009;81(4):747-9
4. Anderson DR, Schwartz J, Hunter NJ, et al. Varicella hepatitis: A fatal case in a previously healthy, immunocompetent adult. Report of a case, autopsy, and review of the literature. Arch Intern Med 1994;154(18):2101-6
5. Lu YC, Fan HC, Wang CC, Cheng SN. Concomitant use of acyclovir and intravenous immunoglobulin rescues an immunocompromised child with disseminated varicella caused multiple organ failure. J Pediatr Hematol Oncol 2010; In press
6. Chilek K, Routhouska S, Tamburro J. Disseminated varicella zoster virus in an immunized child as the acquired immunodeficiency syndrome-defining illness. Pediatr Dermatol 2010;27(2):192-4
7. Zampogna JC, Flowers FP. Persistent verrucous varicella as the initial manifestation of HIV infection. J Am Acad Dermatol 2001;44(2 Suppl):391-4
8. Plisek S, Pliskova L, Bostik V, et al. Fulminant hepatitis and death associated with disseminated varicella in an immunocompromised adult from the Czech Republic caused by a wild-type clade 4 varicella-zoster virus strain. J Clin Virol 2011;50(1):72-5
9. Johnson RW, McElhaney J. Postherpetic neuralgia in the elderly. Int J Clin Pract 2009;63(9):1386-91
10. Johnson RW. Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines 2010;9(3 Suppl):21-6
11. Pickering G, Leplege A. Herpes zoster pain, postherpetic neuralgia, and quality of life in the elderly. Pain Pract 2010; In press
12. Johnson RW, Bouhassira D, Kassianos G, et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010;8:37 A detailed review of the impact of herpes zoster and post-herpetic neuralgia on quality-of-life.
13. Opstelten W, McElhaney J, Weinberger B, et al. The impact of varicella zoster virus: Chronic pain. J Clin Virol 2010;48(Suppl 1):S8-13
14. Sanjay S, Huang P, Lavanya R. Herpes zoster ophthalmicus. Curr Treat Options Neurol 2011;13(1):79-91
15. Vafai A, Berger M. Zoster in patients infected with HIV: A review. Am J Med Sci 2001;321(6):372-80
16. Wauters O, Lebas E, Nikkels AF. Chronic mucocutaneous herpes simplex virus and varicella zoster virus infections. J Am Acad Dermatol 2010; In press
17. Grossman MC, Grossman ME. Chronic hyperkeratotic herpes zoster and human immunodeficiency virus infection. J Am Acad Dermatol 1993;28(2 Pt 2):306-8
18. Mueller NH, Gilden DH, Cohrs RJ, et al. Varicella zoster virus infection: Clinical features, molecular pathogenesis of disease, and latency. Neurol Clin 2008;26(3):675-97; viii
19. Hillenkamp J, Nolle B, Bruns C, et al. Acute retinal necrosis: Clinical features, early vitrectomy, and outcomes. Ophthalmology 2009;116(10):1971-5
20. Austin RB. Progressive outer retinal necrosis syndrome: A comprehensive review of its clinical presentation, relationship to immune system status, and management. Clin Eye Vis Care 2000;12(3-4):119-29 This paper describes the effect of varicella vaccine on varicella-zoster virus dynamics.
21. Yin PD, Kurup SK, Fischer SH, et al. Progressive outer retinal necrosis in the era of highly active antiretroviral therapy: Successful management with intravitreal injections and monitoring with quantitative PCR. J Clin Virol 2007;38(3):254-9
22. Pavesio CE, Mitchell SM, Barton K, et al. Progressive outer retinal necrosis (PORN) in AIDS patients: A different appearance of varicella-zoster retinitis. Eye (Lond) 1995;9(Pt 3):271-6
23. Benz MS, Glaser JS, Davis JL. Progressive outer retinal necrosis in immunocompetent patients treated initially for optic neuropathy with systemic corticosteroids. Am J Ophthalmol 2003;135(4):551-3
24. Schmid DS, Jumaan AO. Impact of varicella vaccine on varicella-zoster virus dynamics. Clin Microbiol Rev 2010;23(1):202-17
25. Vazquez M, Shapiro ED. Varicella vaccine and infection with varicella-zoster virus. N Engl J Med 2005;352(5):439-40
26. Vazquez M. Varicella infections and varicella vaccine in the 21st century. Pediatr Infect Dis J 2004;23(9):871-2
27. Breuer J, Schmid DS. Vaccine Oka variants and sequence variability in vaccine-related skin lesions. J Infect Dis 2008;197(Suppl 2):S54-7
28. Breuer J, Quinlivan M, Al Bassam M, et al. DNA sequence variability in Oka vaccine isolates. J Infect Dis 2007;196(5):801-2
29. Loparev VN, Rubtcova E, Seward JF, et al. DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine. J Infect Dis 2007;195(4):502-10
30. Gnann JW Jr. Vaccination to prevent herpes zoster in older adults. J Pain 2008;9(1 Suppl 1):S31-6
31. Sanford M, Keating GM. Zoster vaccine (Zostavax): A review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging 2010;27(2):159-76
32. Levin MJ, Gershon AA, Dworkin RH, et al. Prevention strategies for herpes zoster and post-herpetic neuralgia. J Clin Virol 2010;48(Suppl 1):S14-19
33. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352(22):2271-84
34. Schmader KE, Johnson GR, Saddier P, et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc 2010;58(9):1634-41
35. Elion GB, Furman PA, Fyfe JA, et al. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 1977;74(12):5716-20
36. Schaeffer HJ, Beauchamp L, de Miranda P, et al. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 1978;272(5654):583-5
37. Fyfe JA, Keller PM, Furman PA, et al. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2- hydroxyethoxymethyl) guanine. J Biol Chem 1978;253(24):8721-7
38. Keller PM, Fyfe JA, Beauchamp L, et al. Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with antiherpetic activities. Biochem Pharmacol 1981;30(22):3071-7
39. Miller WH, Miller RL. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J Biol Chem 1980;255(15):7204-7
40. Miller WH, Miller RL. Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem Pharmacol 1982;31(23):3879-84
41. Derse D, Cheng YC, Furman PA, et al. Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate. Effects on primer-template function. J Biol Chem 1981;256(22):11447-51
42. Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996;52(5):754-72
43. Darby G. Acyclovir-and beyond. J Int Med Res 1994;22(Suppl 1):33A-42A
44. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54(6):595-605
45. Guo A, Hu P, Balimane PV, et al. Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther 1999;289(1):448-54
46. De Clercq E, Field HJ. Antiviral prodrugs - The development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006;147(1):1-11
47. Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996;52(5):754-72
48. Warren T, Harris J, Brennan CA. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV. Clin Infect Dis 2004;39(Suppl 5):S258-66
49. DeJesus E, Wald A, Warren T, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis 2003;188(7):1009-16
50. Beutner KR. Valacyclovir: A review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 1995;28(4):281-90
51. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350(1):11-20
52. Beutner KR, Friedman DJ, Forszpaniak C, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39(7):1546-53
53. Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 2004;190(8):1374-81
54. Perry CM, Wagstaff AJ. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs 1995;50(2):396-415
55. Vere Hodge RA, Sutton D, Boyd MR, et al. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl) guanine; penciclovir]. Antimicrob Agents Chemother 1989;33(10):1765-73
56. Boyd MR, Bacon TH, Sutton D, Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl) guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother 1987;31(8):1238-42
57. Rashidi MR, Smith JA, Clarke SE, Beedham C. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab Dispos 1997;25(7):805-13
58. Simpson D, Lyseng-Williamson KA. Famciclovir: A review of its use in herpes zoster and genital and orolabial herpes. Drugs 2006;66(18):2397-416
59. Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Arch Intern Med 1997;157(3):343-9 A very comprehensive and detailed review of the different strategies used to manage herpes zoster and post-herpetic neuralgia.
60. Sacks SL, Aoki FY, Martel AY, et al. Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: A randomized, double-blind, controlled trial. Clin Infect Dis 2005;41(8):1097-104
61. Wald A, Selke S, Warren T, et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis 2006;33(9):529-33
62. De Clercq E, Descamps J, de Somer P, et al. Walker RT. (E)-5-(2-Bromovinyl)- 2'-deoxyuridine: A potent and selective anti-herpes agent. Proc Natl Acad Sci USA 1979;76(6):2947-51
63. De Clercq E. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem Pharmacol 2004;68(12):2301-15
64. Wutzler P. Antiviral therapy of herpes simplex and varicella-zoster virus infections. Intervirology 1997;40(5-6):343-56
65. Desgranges C, Razaka G, De Clercq E, et al. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res 1986;46(3):1094-101
66. Okuda H, Nishiyama T, Ogura K, et al. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab Dispos 1997;25(2):270-3
67. Okuda H, Ogura K, Kato A, et al. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Ther 1998;287(2):791-9
68. Whitley RJ, Volpi A, McKendrick M, et al. Management of herpes zoster and post-herpetic neuralgia now and in the future. J Clin Virol 2010;48(Suppl 1):S20-8
69. Levy O, Orange JS, Hibberd P, et al. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis 2003;188(7):948-53
70. Galea SA, Sweet A, Beninger P, et al. The safety profile of varicella vaccine: A 10-year review. J Infect Dis 2008;197(Suppl 2):S165-9
71. Ota K, Kim V, Lavi S, et al. Vaccine-strain varicella zoster virus causing recurrent herpes zoster in an immunocompetent 2-year-old. Pediatr Infect Dis J 2008;27(9):847-8
72. Uebe B, Sauerbrei A, Burdach S, Horneff G. Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child. Eur J Pediatr 2002;161(8):442-4
73. Fusco D, Krawitz P, LaRussa P, et al. VZV meningitis following varicella vaccine. J Clin Virol 2010;48(4):275-7
74. Chouliaras G, Spoulou V, Quinlivan M, et al. Vaccine-associated herpes zoster ophthalmicus [correction of opthalmicus] and encephalitis in an immunocompetent child. Pediatrics 2010;125(4):e969-72
75. Pahwa S, Biron K, Lim W, et al. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA 1988;260(19):2879-82
76. Snoeck R, Gerard M, Sadzot-Delvaux C, et al. Meningoradiculoneuritis due to acyclovir-resistant varicella zoster virus in an acquired immune deficiency syndrome patient. J Med Virol 1994;42(4):338-47
77. Boivin G, Edelman CK, Pedneault L, et al. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 1994;170(1):68-75
78. Talarico CL, Phelps WC, Biron KK. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. J Virol 1993;67(2):1024-33
79. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: Clinical impacts and molecular mechanisms. Drug Resist Updat 2002;5(2):88-114
80. Boivin G, Edelman CK, Pedneault L, et al. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 1994;170(1):68-75
81. Morfin F, Thouvenot D, Turenne-Tessier M, et al. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob Agents Chemother 1999;43(10):2412-16
82. Hatchette T, Tipples GA, Peters G, et al. Foscarnet salvage therapy for acyclovir-resistant varicella zoster: Report of a novel thymidine kinase mutation and review of the literature. Pediatr Infect Dis J 2008;27(1):75-7
83. Safrin S, Berger TG, Gilson I, et al. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicellazoster virus infection. Ann Intern Med 1991;115(1):19-21
84. Bryan CJ, Prichard MN, Daily S, et al. Acyclovir-resistant chronic verrucous vaccine strain varicella in a patient with neuroblastoma. Pediatr Infect Dis J 2008;27(10):946-8
85. Visse B, Dumont B, Huraux JM, Fillet AM. Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. J Infect Dis 1998;178(Suppl 1):S55-7
86. Fillet AM, Visse B, Caumes E, et al. Clin Infect Dis 1995;21(5):1348-9
87. Visse B, Huraux JM, Fillet AM. Point mutations in the varicella-zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype. J Med Virol 1999;59(1):84-90
88. Kamiyama T, Kurokawa M, Shiraki K. Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir. J Gen Virol 2001;82(Pt 11):2761-5
89. Andrei G, De Clercq E, Snoeck R. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): Differences between acyclovir and penciclovir? Antiviral Res 2004;61(3):181-7
90. Boyd MR, Bacon TH, Sutton D, Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl) guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother 1987;31(8):1238-42
91. Pelosi E, Mulamba GB, Coen DM. Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants. Antiviral Res 1998;37(1):17-28
92. Hasegawa T, Kurokawa M, Yukawa TA, et al. Inhibitory action of acyclovir (ACV) and penciclovir (PCV) on plaque formation and partial cross-resistance of ACV-resistant varicella-zoster virus to PCV. Antiviral Res 1995;27(3):271-9
93. Ida M, Kageyama S, Sato H, et al. Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants. Antiviral Res 1999;40(3):155-66
94. Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: Mechanisms, prevalence, and management. Antimicrob Agents Chemother 2011;55(2):459-72 Important study on the preclinical development of the bicyclic nucleoside analogue FV-100 as potent and selective inhibitors of varicella zoster virus.
95. Snoeck R, De Clercq E. Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients. Curr Opin Investig Drugs 2002;3(11):1561-6
96. Levin MJ, Dahl KM, Weinberg A, et al. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J Infect Dis 2003;188(7):954-9
97. McGuigan C, Yarnold CJ, Jones G, et al. Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base. J Med Chem 1999;42(22):4479-84
98. Srinivasan S, McGuigan C, Andrei G, et al. Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): The effect of terminal unsaturation in the side chain. Bioorg Med Chem Lett 2001;11(3):391-3
99. Brancale A, McGuigan C, Andrei G, et al. Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): The effect of a terminal halogen substitution in the side-chain. Bioorg Med Chem Lett 2000;10(11):1215-17
100. Brancale A, McGuigan C, Algain B, et al. Bicyclic anti-VZV nucleosides: Thieno analogues retain full antiviral activity. Bioorg Med Chem Lett 2001;11(18):2507-10
101. McGuigan C, Pathirana RN, Jones G, et al. Anti-varicella-zoster virus bicyclic nucleosides: Replacement of furo by pyrro base reduces antiviral potency. Antivir Chem Chemother 2000;11(5):343-8
102. McGuigan C, Barucki H, Carangio A, et al. Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. J Med Chem 2000;43(26):4993-7
103. Balzarini J, McGuigan C. Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides. Biochim Biophys Acta 2002;1587(2-3):287-95
104. Andrei G, Sienaert R, McGuigan C, et al. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides. Antimicrob Agents Chemother 2005;49(3):1081-6
105. McGuigan C, Pathirana RN, Migliore M, et al. Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. J Antimicrob Chemother 2007;60(6):1316-30
106. Brancale A, Srinivasan S, McGuigan C, et al. Synthesis and anti-varicella-zoster virus activity of some novel bicyclic nucleoside inhibitors: Effect of enhanced aqueous solubility. Antivir Chem Chemother 2000;11(6):383-93 Description of the ASP2151, a novel helicase-primase inhibitor, with antiviral activity against varicella-zoster virus and herpes simplex virus.
107. Sienaert R, Naesens L, Brancale A, et al. Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol Pharmacol 2002;61(2):249-54
108. Sienaert R, Naesens L, Brancale A, et al. Metabolic and pharmacological characteristics of the bicyclic nucleoside analogues (BCNAs) as highly selective inhibitors of varicella-zoster virus (VZV). Nucleosides Nucleotides Nucleic Acids 2003;22(5-8):995-7 Study on the characterization of H2G-resistant VZV mutants.
109. Balzarini J, Sienaert R, Liekens S, et al. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Mol Pharmacol 2002;61(5):1140-5
110. Spector FC, Liang L, Giordano H, et al. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. J Virol 1998;72(9):6979-87
111. Kleymann G, Fischer R, Betz UA, et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med 2002;8(4):392-8
112. Baumeister J, Fischer R, Eckenberg P, et al. Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease. Antivir Chem Chemother 2007;18(1):35-48
113. Crute JJ, Grygon CA, Hargrave KD, et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med 2002;8(4):386-91
114. Kleymann G. New antiviral drugs that target herpesvirus helicase primase enzymes. Herpes 2003;10(2):46-52
115. Chen X, Adrian J, Cushing T, et al. SAR studies on a novel series of human cytomegalovirus primase inhibitors. Bioorg Med Chem Lett 2007;17(8):2188-92
116. Cushing TD, Adrian J, Chen X, et al. Discovery of a novel series of inhibitors of human cytomegalovirus primase. Bioorg Med Chem Lett 2006;16(18):4879-83
117. Chono K, Katsumata K, Kontani T, et al. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J Antimicrob Chemother 2010;65(8):1733-41
118. Abele G, Eriksson B, Harmenberg J, Wahren B. Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl] guanine triphosphate. Antimicrob Agents Chemother 1988;32(8):1137-42
119. Lowe DM, Alderton WK, Ellis MR, et al. Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine against herpesviruses. Antimicrob Agents Chemother 1995;39(8):1802-8
120. De Clercq E, Naesens L, De Bolle L, et al. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Med Virol 2001;11(6):381-95
121. Bonnafous P, Agut H. Activity of H2G on human herpesvirus-6B strains either sensitive or resistant to ganciclovir. J Clin Virol 2010;48(2):153-4
122. Ng TI, Shi Y, Huffaker HJ, et al. Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy) butyl] guanine. Antimicrob Agents Chemother 2001;45(6):1629-36
123. Neyts J, Andrei G, De Clercq E. The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil. Antimicrob Agents Chemother 1998;42(12):3285-9
124. Balfour HH Jr, Vezina HE, Hogquist RC, et al. Randomized, placebo-controlled, double-blind trial of valomaciclovir (VALM) for infectious mononucleosis (IM) [abstract V1256a.: P221]. 49th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotheray; 14 September 2009; San Francisco, CA
125. Visalli RJ, Fairhurst J, Srinivas S, et al. Identification of small molecule compounds that selectively inhibit varicella-zoster virus replication. J Virol 2003;77(4):2349-58
126. Bloom JD, Dushin RG, Curran KJ, et al. Thiourea inhibitors of herpes viruses. Part 2: N-Benzyl-N'-arylthiourea inhibitors of CMV. Bioorg Med Chem Lett 2004;14(13):3401-6
127. Cardin RD, Bravo FJ, Sewell AP, et al. Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection. Virol J 2009;6:214
128. Bernstein DI, Goyette N, Cardin R, et al. Amphipathic DNA polymers exhibit antiherpetic activity in vitro and in vivo. Antimicrob Agents Chemother 2008;52(8):2727-33
129. Guzman EM, Cheshenko N, Shende V, et al. Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression. Antivir Ther 2007;12(8):1147-56
130. Vaillant A, Juteau JM, Lu H, et al. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. Antimicrob Agents Chemother 2006;50(4):1393-401
131. Matsumura T, Hu Z, Kato T, et al. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology 2009;137(2):673-81
132. Kern ER, Prichard MN, Quenelle DC, et al. Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections. Antimicrob Agents Chemother 2009;53(2):572-9
133. Prichard MN, Quenelle DC, Hartline CB, et al. Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. Antimicrob Agents Chemother 2009;53(12):5251-8
134. Snoeck R, De Clercq E. Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients. Curr Opin Investig Drugs 2002;3(11):1561-6
135. De Clercq E, Holy A. Acyclic nucleoside phosphonates: A key class of antiviral drugs. Nat Rev Drug Discov 2005;4(11):928-40
136. Xiong X, Smith JL, Kim C, et al. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochem Pharmacol 1996;51(11):1563-7
137. Xiong X, Smith JL, Chen MS. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob Agents Chemother 1997;41(3):594-9
138. Beadle JR, Hartline C, Aldern KA, et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother 2002;46(8):2381-6
139. Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art. Antiviral Res 2009;82(2):A84-98
140. Hostetler KY, Rought S, Aldern KA, et al. Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro. Mol Cancer Ther 2006;5(1):156-9
141. Andrei G, Snoeck R, Schols D, De Clercq E. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res 2000;12(9-10):397-408
142. Snoeck R. Papillomavirus and treatment. Antiviral Res 2006;71(2-3):181-91
143. Andrei G, Snoeck R, Vandeputte M, De Clercq E. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother 1997;41(3):587-93
144. Lebeau I, Andrei G, Krecmerova M, et al. Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains. Antimicrob Agents Chemother 2007;51(6):2268-73
145. Hartline CB, Harden EA, Williams-Aziz SL, et al. Inhibition of herpesvirus replication by a series of 4-oxo-dihydroquinolines with viral polymerase activity. Antiviral Res 2005;65(2):97-105
146. Aldern KA, Ciesla SL, Winegarden KL, Hostetler KY. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C] cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol 2003;63(3):678-81
147. Kern ER, Collins DJ, Wan WB, et al. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004;48(9):3516-22
148. Bidanset DJ, Beadle JR, Wan WB, et al. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J Infect Dis 2004;190(3):499-503
149. Wan WB, Beadle JR, Hartline C, et al. Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob Agents Chemother 2005;49(2):656-62
150. Keith KA, Wan WB, Ciesla SL, et al. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro. Antimicrob Agents Chemother 2004;48(5):1869-71
151. Quenelle DC, Collins DJ, Wan WB, et al. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004;48(2):404-12 First report of the synthesis and antiviral activity of the 5-aza derivative of cidofovir.
152. Ciesla SL, Trahan J, Wan WB, et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res 2003;59(3):163-71
153. Kern ER, Collins DJ, Wan WB, et al. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004;48(9):3516-22
154. Painter GR, Hostetler KY. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol 2004;22(8):423-7
155. Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art. Antiviral Res 2009;82(2):A84-98
156. Ruiz JC, Aldern KA, Beadle JR, et al. Synthesis and antiviral evaluation of alkoxyalkyl esters of phosphonopropoxymethyl-guanine and phosphonopropoxymethyldiaminopurine. Antivir Chem Chemother 2006;17(2):89-95
157. Ruiz JC, Beadle JR, Aldern KA, et al. Synthesis and antiviral evaluation of alkoxyalkyl-phosphate conjugates of cidofovir and adefovir. Antiviral Res 2007;75(1):87-90
158. Dal Pozzo F, Andrei G, Lebeau I, et al. In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA. Antiviral Res 2007;75(1):52-7
159. Beadle JR, Wan WB, Ciesla SL, et al. Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3- hydroxy-2-phosphonomethoxypropyl) adenine against cytomegalovirus and orthopoxviruses. J Med Chem 2006;49(6):2010-15
160. Lebeau I, Andrei G, Dal Pozzo F, et al. Activities of alkoxyalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9- (3-hydroxy-2-phosphonylmethoxypropyl) adenine against orthopoxviruses in cell monolayers and in organotypic cultures. Antimicrob Agents Chemother 2006;50(7):2525-9
161. Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art. Antiviral Res 2009;82(2):A84-98
162. De Clercq E. The acyclic nucleoside phosphonates from inception to clinical use: Historical perspective. Antiviral Res 2007;75(1):1-13
163. Balzarini J, Pannecouque C, Naesens L, et al. 6-[2-phosphonomethoxy) alkoxy]- 2,4-diaminopyrimidines: A new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity. Nucleosides Nucleotides Nucleic Acids 2004;23(8-9):1321-7
164. Hockova D, Holy A, Masojidkova M, et al. 5-Substituted-2,4-diamino-6-[2- (phosphonomethoxy)ethoxy]pyrimidinesacyclic nucleoside phosphonate analogues with antiviral activity. J Med Chem 2003;46(23):5064-73
165. Hockova D, Holy A, Masojidkova M, et al. Synthesis and antiviral activity of 2,4-diamino-5-cyano-6-[2- (phosphonomethoxy)ethoxy]pyrimidine and related compounds. Bioorg Med Chem 2004;12(12):3197-202
166. De Clercq E, Andrei G, Balzarini J, et al. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy) alkoxy]-2,4- diaminopyrimidines. Nucleosides Nucleotides Nucleic Acids 2005;24(5-7):331-41
167. Krecmerova M, Holy A, Pohl R, et al. Ester prodrugs of cyclic 1-(S)-[3- hydroxy-2-(phosphonomethoxy)propyl]- 5-azacytosine: Synthesis and antiviral activity. J Med Chem 2007;50(23):5765-72
168. Krecmerova M, Holy A, Piskala A, et al. Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy) propyl]cytosine (cidofovir) and related compounds. J Med Chem 2007;50(5):1069-77
169. Krecmerova M, Holy A, Pohl R, et al. Ester prodrugs of cyclic 1-(S)-[3- hydroxy-2-(phosphonomethoxy)propyl]- 5-azacytosine: Synthesis and antiviral
170. Topalis D, Lebeau I, Krecmerova M, et al. Activity of different classes of acyclic nucleoside phosphonates against BK virus in primary human renal cells. Antimicrob Agents Chemother 2011;55(5):1961-7
171. Schang LM. Cyclin-dependent kinases as cellular targets for antiviral drugs. J Antimicrob Chemother 2002;50(6):779-92
172. Schang LM, St Vincent MR, Lacasse JJ. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antivir Chem Chemother 2006;17(6):293-320
173. Guendel I, Agbottah ET, Kehn-Hall K, Kashanchi F. Inhibition of human immunodeficiency virus type-1 by cdk inhibitors. AIDS Res Ther 2010;7(1):7
174. Orba Y, Sunden Y, Suzuki T, et al. Pharmacological cdk inhibitor R-Roscovitine suppresses JC virus proliferation. Virology 2008;370(1):173-83
175. Schang LM. First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy. Expert Rev Anti Infect Ther 2006;4(6):953-6
176. Yang H, Kim SK, Kim M, et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest 2005;115(2):379-87
177. Reeves PM, Bommarius B, Lebeis S, et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med 2005;11(7):731-9
178. Rowe J, Greenblatt RJ, Liu D, Moffat JF. Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice. Antiviral Res 2010;86(3):276-85
179. Messaoudi I, Barron A, Wellish M, et al. Simian varicella virus infection of rhesus macaques recapitulates essential features of varicella zoster virus infection in humans. PLoS Pathog 2009;5(11):e1000657